Table 2.

Association of MTHFR genotype and risk of recurrent adenomas

Genotype
Any adenoma
Advanced adenoma*
677C>T (n)No.RR (95% CI)No.RR (95% CI)
CC (405)1821.0451.0
CT (400)1770.97 (0.83-1.14)370.81 (0.36-1.55)
TT (93)360.89 (0.68-1.16)80.75 (0.36-1.55)
P for trend0.420.28
1298A>C (n)
AA (444)1821.0431.0
AC (379)1781.14 (0.98-1.33)381.03 (0.68-1.57)
CC (77)361.14 (0.87-1.50)91.16 (0.58-2.33)
P for trend0.120.71
MTHFR 677/1298 genotype
No.
RR (95% CI)
No.
RR (95% CI)
CC/AA (137)551.0141.0
CC/AC (192)911.17 (0.90-1.51)221.08 (0.56-2.07)
CC/CC (76)361.17 (0.85-1.60)91.05 (0.47-2.37)
CT/AA (214)911.03 (0.80-1.33)210.89 (0.47-1.72)
CT/AC (186)861.14 (0.88-1.47)160.79 (0.40-1.58)
TT/AA (93)360.98 (0.72-1.35)80.78 (0.34-1.81)
  • * Advanced adenoma defined as >25% tubulovillous or villous adenoma, large adenoma (≥1 cm), advanced dysplasia, carcinoma in situ, or invasive cancer.

  • RRs were adjusted for age, sex, clinical center, treatment assignment, and follow-up time.

  • Wald test used to generate P values.